P

Procept Biorobotics Corp
NASDAQ:PRCT

Watchlist Manager
Procept Biorobotics Corp
NASDAQ:PRCT
Watchlist
Price: 30.76 USD -2.23% Market Closed
Market Cap: 1.7B USD

Procept Biorobotics Corp
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Procept Biorobotics Corp
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
P
Procept Biorobotics Corp
NASDAQ:PRCT
Free Cash Flow
-$103.6m
CAGR 3-Years
-21%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Free Cash Flow
$2.7B
CAGR 3-Years
17%
CAGR 5-Years
-1%
CAGR 10-Years
9%
Boston Scientific Corp
NYSE:BSX
Free Cash Flow
$3.8B
CAGR 3-Years
85%
CAGR 5-Years
31%
CAGR 10-Years
24%
Stryker Corp
NYSE:SYK
Free Cash Flow
$4.1B
CAGR 3-Years
26%
CAGR 5-Years
13%
CAGR 10-Years
20%
Abbott Laboratories
NYSE:ABT
Free Cash Flow
$6.9B
CAGR 3-Years
-7%
CAGR 5-Years
9%
CAGR 10-Years
12%
Intuitive Surgical Inc
NASDAQ:ISRG
Free Cash Flow
$2.3B
CAGR 3-Years
28%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Procept Biorobotics Corp
Glance View

Market Cap
1.7B USD
Industry
Health Care

Procept Biorobotics Corp. is a pioneering force in the medical technology landscape, blending innovative engineering with clinical insights to address some of the most pressing challenges in urology. Founded with a vision to revolutionize surgical care, the company developed the AquaBeam Robotic System, an advanced medical platform that leverages robotic precision and real-time ultrasound imaging. This system is primarily employed in performing Aquablation therapy, a minimally invasive treatment designed to alleviate symptoms of benign prostatic hyperplasia (BPH). By integrating robotics and imaging, Procept offers a solution that enhances the accuracy of prostate tissue removal while minimizing risks and downtime for patients—a significant advancement over conventional methods. Revenue generation for Procept Biorobotics centers on the sales of their AquaBeam systems, along with consumables and service contracts that provide ongoing support and upgrades for their hospital and clinical partners. Recognizing the critical nature of procedure efficiency and safety, the company also invests in broadening the application of its technology and frequently seeks endorsements through clinical trials and studies to validate their innovations. By ensuring their cutting-edge solutions meet the stringent demands of healthcare professionals and patients alike, Procept maintains a competitive edge, fostering both adoption and trust within the healthcare community while steadily driving their growth and financial success.

PRCT Intrinsic Value
20.47 USD
Overvaluation 33%
Intrinsic Value
Price
P

See Also

What is Procept Biorobotics Corp's Free Cash Flow?
Free Cash Flow
-103.6m USD

Based on the financial report for Dec 31, 2024, Procept Biorobotics Corp's Free Cash Flow amounts to -103.6m USD.

What is Procept Biorobotics Corp's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-15%

Over the last year, the Free Cash Flow growth was 22%. The average annual Free Cash Flow growth rates for Procept Biorobotics Corp have been -21% over the past three years , -15% over the past five years .

Back to Top